The Decadal Shift: Antibiotics as a Definitive Option for Uncomplicated Appendicitis
The management of acute appendicitis, long considered a surgical emergency requiring immediate appendectomy, has undergone a fundamental transformation. For over a century, the dogma was clear: an inflamed appendix must be removed to prevent perforation and peritonitis. However, the emergence of high-quality randomized controlled trials (RCTs) has challenged this ‘surgery-first’ approach. The Appendicitis Acuta (APPAC) trial is perhaps the most influential of these studies. With the publication of its 10-year follow-up data in JAMA, the medical community now has definitive evidence regarding the long-term durability, safety, and patient outcomes of non-operative management.
Highlights of the 10-Year APPAC Follow-Up
The 10-year analysis provides critical insights into the natural history of uncomplicated appendicitis treated with antibiotics. Key takeaways include:
Long-Term Success Rate
Approximately 62.2% of patients who were initially treated with antibiotics did not require an appendectomy during the 10-year follow-up period.
Safety Profile
The cumulative complication rate was significantly lower in the antibiotic group (8.5%) compared to the appendectomy group (27.4%), highlighting the avoidance of surgical risks such as incisional hernias and surgical site infections.
Recurrence Patterns
While most recurrences occur within the first year, late recurrences do happen, but they do not lead to increased morbidity or a higher risk of perforated appendicitis.
Quality of Life
There were no significant differences in long-term quality of life or patient satisfaction between those who underwent surgery and those treated with antibiotics.
Background: Challenging the Surgical Paradigm
Uncomplicated acute appendicitis is defined by the absence of an appendicolith, perforation, abscess, or suspicion of a tumor. Traditionally, appendectomy was the gold standard due to fears that antibiotics alone would lead to high recurrence rates and eventual complications. The APPAC trial was designed to rigorously test whether a ‘cold’ approach with antibiotics could provide a safe alternative. Previous reports from this trial at 1-year and 5-year intervals showed promising results, but the 10-year data was eagerly awaited to determine if the benefits of avoiding surgery would persist or if late recurrences would eventually drive most patients to the operating room.
Study Design and Methodology
The APPAC trial was a multicenter, open-label, non-inferiority randomized clinical trial conducted at six Finnish hospitals. Between November 2009 and June 2012, 530 patients aged 18 to 60 with computed tomography (CT)-confirmed uncomplicated acute appendicitis were enrolled.
Interventions
Patients were randomized to two groups: 1) The Appendectomy Group (n = 273), who underwent standard open appendectomy. 2) The Antibiotic Group (n = 257), who received intravenous ertapenem (1 g/day) for 3 days, followed by 7 days of oral levofloxacin (500 mg once daily) and metronidazole (500 mg three times daily).
Endpoints and Follow-Up
The primary endpoint for the original study was the success of the treatment. For this 10-year follow-up, the secondary endpoints included the rate of late appendectomy, appendicitis recurrence, and complications. Post hoc analyses also looked at quality of life (using the EuroQol-5D-5L index) and the potential for missed appendiceal tumors, which were assessed via MRI or histopathology in those who eventually had surgery.
Key Findings: A Decade of Data
The results at the 10-year mark reinforce the viability of the non-operative approach. Out of the 257 patients randomized to antibiotics, 253 were available for the 10-year assessment.
Appendectomy and Recurrence Rates
The cumulative appendectomy rate in the antibiotic group was 44.3% (112/253) at 10 years. This means that nearly 56% of the original cohort successfully avoided surgery entirely. When looking specifically at ‘true’ recurrences (confirmed by histopathology), the rate was 37.8%. Most recurrences (70/100) occurred within the first year, but the data showed that the risk of recurrence continues to diminish over time, with very few cases occurring between years 5 and 10.
Complications and Safety
One of the strongest arguments for the antibiotic approach is the reduction in treatment-related morbidity. The complication rate in the appendectomy group was 27.4%, primarily driven by surgical site infections and incisional hernias. In contrast, the antibiotic group had a complication rate of only 8.5%. Importantly, there was no evidence that delaying surgery in the antibiotic group led to more complex or perforated cases of appendicitis when a recurrence did occur.
The Question of Appendiceal Tumors
A common clinical concern with non-operative management is the potential for missing an underlying appendiceal neoplasm. In this 10-year follow-up, the researchers utilized MRI and histopathological review. No missed tumors were identified in the antibiotic group, suggesting that the risk is minimal in patients diagnosed with uncomplicated appendicitis via high-quality CT imaging.
Expert Commentary: Clinical Implications
The APPAC 10-year data provides clinicians with a robust evidence base for shared decision-making. For a patient with uncomplicated appendicitis, the choice is no longer between ‘cure’ and ‘failure,’ but between ‘definitive surgical removal’ and ‘an approximately 60% chance of avoiding surgery for life.’
Shared Decision-Making
Clinicians should present these findings to patients, emphasizing that while surgery is definitive, it carries a higher risk of short- and long-term complications (like hernias). Antibiotics offer a faster recovery and lower complication rates, but with a roughly 40% chance of requiring surgery later. For many patients, especially those who wish to avoid the risks of general anesthesia or a hospital stay, antibiotics are a highly attractive first-line option.
Economic and Systemic Impact
From a health policy perspective, the non-operative approach can reduce the burden on surgical theaters and lower immediate healthcare costs, though these must be balanced against the costs of potential readmissions for recurrence.
Conclusion
The 10-year follow-up of the APPAC trial is a landmark in surgical research. It confirms that antibiotic therapy is not just a temporary measure, but a durable and safe long-term treatment strategy for uncomplicated acute appendicitis in adults. As the medical community moves toward more personalized and less invasive care, these findings support the inclusion of antibiotics as a standard-of-care option in clinical guidelines.
Funding and Trial Registration
This study was supported by the Mary and Georg C. Ehrnrooth Foundation and the Government Research Grant (EVO). The trial is registered at ClinicalTrials.gov (NCT01022567).
References
Salminen P, Salminen R, Kallio J, et al. Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial. JAMA. 2026;335(3):e2525921. doi:10.1001/jama.2025.25921.